Kinnate Biopharma Inc.
Kinnate Biopharma Inc. (KNTE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
knte · stock forecast · 6 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$30.00
+1032.1% upside
Low
$30.00
Median: $30 · Last Close: $2.65
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.68 | ↑ 1.12% |
1-day model range: $2.67–$2.69. Peak: $2.69 (+1.12%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · KNTE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-02-26 | Stifel | Maintains | Hold→Hold |
| 2024-01-17 | Wedbush | Maintains | Neutral→Neutral |
| 2023-09-19 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-09-19 | Jefferies | Maintains | Buy→Buy |
| 2023-09-19 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-09-19 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-09-18 | Jefferies | Maintains | Buy→Buy |
| 2023-09-18 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-09-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-09-18 | Wedbush | Downgrade ↓ | Outperform→Neutral |
Wall Street analysts have recently issued updated ratings on Kinnate Biopharma Inc. (KNTE) stock. Of the recent 35 rating actions, 0 were upgrades and 8 were downgrades. 6 analysts currently cover KNTE.
Analyst Recommendation Trends
KNTE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-1.04
EPS Next Year
$-0.87
↓ 16.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast KNTE EPS of $-1.04 for the current fiscal year, based on estimates from 4 analysts. The KNTE revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KNTE stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KNTE price target is $30.00 (+1032.1% upside), with an analyst consensus of Hold.
The KNTE short-term stock prediction for tomorrow is $2.68 (+1.12%).
Kinnate Biopharma Inc. trades on NASDAQ under the ticker KNTE. The KNTE stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
KNTE forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month KNTE price target is $30.00, with a high forecast of $30.00 and a low of $30.00. The median price target is shown in the chart above when available. This implies +1032.1% potential upside from the current price of $2.65.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.